Co-Authors
This is a "connection" page, showing publications co-authored by YING YUAN and DAVID SANGHYUN HONG.
Connection Strength
0.807
-
Clinical and genomic landscape of RAS mutations in gynecologic cancers. Clin Cancer Res. 2024 Apr 30.
Score: 0.247
-
Predictors of Oncologic Outcome in Patients Receiving Phase I Investigational Therapy for Recurrent or Metastatic Cervical Cancer. J Immunother Precis Oncol. 2023 Feb; 6(1):10-18.
Score: 0.226
-
Inhibition of the CD47-SIRPa axis for cancer therapy: A systematic review and meta-analysis of emerging clinical data. Front Immunol. 2022; 13:1027235.
Score: 0.223
-
Phase I Study of mTORC1/2 Inhibitor Sapanisertib (CB-228/TAK-228) in Combination with Metformin in Patients with mTOR/AKT/PI3K Pathway Alterations and Advanced Solid Malignancies. Cancer Res Commun. 2024 02 12; 4(2):378-387.
Score: 0.061
-
High-dose irradiation in combination with non-ablative low-dose radiation to treat metastatic disease after progression on immunotherapy: Results of a phase II trial. Radiother Oncol. 2021 09; 162:60-67.
Score: 0.051